Title : Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.

Pub. Date : 1996 Jul

PMID : 8831918






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The highest activation of LPL was obtained after treatment with 200 mg ciprofibrate/day. ciprofibrate lipoprotein lipase Homo sapiens
2 A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters. ciprofibrate lipoprotein lipase Homo sapiens
3 A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters. ciprofibrate lipoprotein lipase Homo sapiens
4 A dose of 200 mg ciprofibrate/day is more effective than 100 mg ciprofibrate/day at increasing LPL and HL activity; however, 200 mg ciprofibrate/day is also associated with a potential detrimental change in safety parameters. ciprofibrate lipoprotein lipase Homo sapiens